Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Johnson & Johnson : Ethicon Transvaginal Mesh Lawsuits Move Forward in Pennsylvania, As Sixth Trial Kicks Off in Philadelphia, Bernstein Liebhard LLP Reports

share with twitter share with LinkedIn share with facebook
share via e-mail
08/17/2017 | 05:56pm CEST

By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- A Pennsylvania jury is now hearing evidence in the state's sixth trial involving allegedly defective transvaginal mesh devices marketed by Johnson & Johnson and its Ethicon, Inc. subsidiary. According to court documents pending in the Philadelphia Court of Common Pleas, this latest case was filed on behalf of a woman who claims that two of the companies' allegedly defective implants caused her to suffer painful and permanent complications, including damage to her urethra that resulted in incontinence. (In Re: Pelvic Mesh Litigation, Case No. 140200829)

"Our Firm is representing hundreds of women who allegedly experienced similar problems due to pelvic mesh devices manufactured by Ethicon and other companies. We will monitor this trial closely, as the verdict could provide clues as to how other juries will rule in similar transvaginal mesh lawsuits," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to evaluate potential legal claims on behalf of women who allegedly developed life-changing complications following implantation of transvaginal mesh (see also Pharmaceutical Companies).

Ethicon Transvaginal Mesh Litigation

Johnson & Johnson and Ethicon have been named defendants in more than 55,000 transvaginal mesh lawsuits pending nationwide. Women pursuing these claims say they experienced a wide range of painful complications, including the erosion of mesh into the vaginal wall, adhesions and scarring, chronic infections, permanent pain, and incontinence, due to the allegedly faulty implants. They further allege that Ethicon and Johnson & Johnson were aware of these defects, but failed to provide patients and doctors with appropriate warning regarding these risks.

So far, Johnson & Johnson and Ethicon have won only one transvaginal mesh trial in Pennsylvania. The first to involve the companies' devices concluded in December 2015, with a $12.5 million verdict for the plaintiffs. In February 2016, a second Pennsylvania jury awarded $13.6 million to another plaintiff, including $10 million in punitive damage. A third case concluded this past April, when Johnson & Johnson and Ethicon were ordered to pay a $20 million judgment, including $17.5 million in punitive damages.

The defendants' sole victory came in June. However, that win was placed in jeopardy last month, when the Court granted the plaintiff's post-trial motion for a new damages hearing.

Transvaginal mesh devices are indicated to treat women who suffer from pelvic organ prolapse and stress urinary incontinence. In 2008, the U.S. Food & Drug Administration (FDA) warned that such devices had been associated with at least 1,000 reports of serious injuries and complications over a three-year period. In July 2011, the agency reported that complications related to transvaginal prolapse repair had tripled since the release of its previous warning. Among other things, the FDA reversed its stance that such injuries were rare.

In 2016, the FDA finalized regulations that reclassified pelvic mesh indicated for transvaginal prolapse repair as Class III (high risk) medical devices. The new rules also made transvaginal mesh ineligible for the agency's 510(k) clearance program, which had previously allowed such products to come to market without first undergoing human clinical trial

Women who suffered serious complications allegedly associated with transvaginal mesh may be entitled to compensation for medical bills, lost wages, pain and suffering and more. To learn more, please visit Bernstein Liebhard LLP's website, or call 800-511-5092 to arrange for a free, no-obligation review of your potential claim.

Keywords for this news article include: Pharmaceutical Companies, ETHICON GmbH, Legal Issues, Bernstein Liebhard Llp.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
08/17 JOHNSON & JOHNSON : Ethicon Transvaginal Mesh Lawsuits Move Forward in Pennsylva..
08/17 JOHNSON & JOHNSON : Announces Partnership with CSIR IMTECH to Develop Innovative..
08/17 JOHNSON & JOHNSON (NYSE : JNJ) Denies Talc Powder Ovarian Cancer-Link In Califor..
08/17 Chinas HitGen bags new drug discovery deal with Aduro
08/17 JOHNSON & JOHNSON : Cerecor CEO retires after scoring Johnson & Johnson license ..
08/16 INSIDER TRADING ACTIVITY NEVRO CORP. : NVRO) – CFO Sold 7,000 shares of St..
08/15 JOHNSON & JOHNSON : candal' of vaginal mesh removal rates revealed by NHS record..
08/14 JOHNSON & JOHNSON : to Participate in 2017 Morgan Stanley Global Health Care Con..
08/14 JOHNSON & JOHNSON : Duct tape evolves from ammo boxes to artwork
08/12 JOHNSON & JOHNSON : Chinese medical expert cautions against premature approval o..
More news
News from SeekingAlpha
08/18 J&J, Bayer log third straight court win over Xarelto
08/18 Dow 'Safer' Dividend Dogs Hound IBM, Pfizer, & Home Depot Top Gainers Per Aug..
08/18 Hundred Thousand Dollars Income Portfolio - The Market Is Simply Overpriced
08/18 JOHNSON & JOHNSON : Sell
08/18 DISNEY : It's All About 3 Things - Iger, Iger And Iger Management
Financials ($)
Sales 2017 75 842 M
EBIT 2017 22 815 M
Net income 2017 16 213 M
Debt 2017 17 708 M
Yield 2017 2,53%
P/E ratio 2017 22,08
P/E ratio 2018 17,96
EV / Sales 2017 4,93x
EV / Sales 2018 4,46x
Capitalization 355 979 M
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 21
Average target price 136 $
Spread / Average Target 2,8%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.12%355 979
NOVARTIS8.84%216 915
ROCHE HOLDING LTD.4.99%216 699
PFIZER0.59%194 554
SANOFI6.97%122 127